Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.

Levra M, Giaj; FE, Cotté; R, Corre; C, Calvet; AF, Gaudin; JR, Penrod; V, Grumberg; B, Jouaneton; R, Jolivel; JB, Assié; C, Chouaïd

doi:10.1016/j.lungcan.2019.12.017

Public

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.

Shared by NobleBlocks on Dec 31, 2019 • 12:00 AM UTC

Authors:

Giaj Levra M

Cotté FE

Corre R

Abstract

<h4>Objectives</h4>Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolumab and on the interest of a second course ...

Subject

Immunotherapy

Non-small cell lung cancer

Real-world Setting

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!